Alpha Tau Medical (DRTS) vs Nektar Therapeutics (NKTR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alpha Tau Medical (DRTS) has outperformed Nektar Therapeutics (NKTR) over the past year, gaining 245.0% versus a loss of 30.6%. Over five years, DRTS leads with a +44.1% price change compared with -84.5% for NKTR. Nektar Therapeutics is the larger company by market cap ($1.39 billion vs $1.28 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DRTS | NKTR |
|---|---|---|
| Share price | $13.82 | $40.73 |
| Market cap | $1.28B | $1.39B |
| 1-day change | -3.00% | +1.15% |
| YTD return | +187.88% | -4.78% |
| 1-year return | +245.04% | -30.59% |
| 5-year return | +44.08% | -84.49% |
| EPS (TTM) | $-1.04 | $-18.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.79 | $109.00 |
| 52-week low | $3.43 | $33.40 |
| Distance from 52-week high | -12.46% | -62.64% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +28.78% | +247.21% |
| Average volume | 566.95K | 1.06M |
| Shares outstanding | 92.48M | 34.14M |
| Employees | 121 | 63 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DRTS has outperformed NKTR by 275.6 percentage points over the past year.
About Alpha Tau Medical
DRTS stock →Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors.
Health Care · Medical/Dental Instruments · 121 employees
About Nektar Therapeutics
NKTR stock →Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
DRTS vs NKTR FAQ
Which is bigger, Alpha Tau Medical or Nektar Therapeutics?
Nektar Therapeutics (NKTR) is larger, with a market capitalization of $1.39B compared with $1.28B for Alpha Tau Medical (DRTS).
Which stock has performed better over the past year, DRTS or NKTR?
DRTS returned +245.04% over the past 12 months, compared with -30.59% for NKTR (price return, excluding dividends). Past performance does not predict future results.
Are Alpha Tau Medical and Nektar Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Alpha Tau Medical and Biotechnology: Pharmaceutical Preparations for Nektar Therapeutics.